Sorafenib: Difference between revisions
David Canner (talk | contribs) No edit summary |
No edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
< | <StructureSection load='' size='450' side='right' scene='Sorafenib/Sorafenib/1' caption='Sorafenib, also known as Nexavar, ([[3heg]])'> | ||
__TOC__ | |||
===Better Known as: Nexavar=== | ===Better Known as: Nexavar=== | ||
* Marketed By: Bayer Healthcare & Onyx Pharmaceuticals<br /> | * Marketed By: Bayer Healthcare & Onyx Pharmaceuticals<br /> | ||
* Major Indication: Renal Cell Carcinoma & Kidney [[Cancer]]<br /> | * Major Indication: Renal Cell Carcinoma & Kidney [[Cancer]]<br /> | ||
* Drug Class: Receptor Tyrosine Kinase (Including [[VEGFR]] & PDGFR) & KIT Cytokine Receptor Inhibitor | * Drug Class: [[Receptor tyrosine kinases|Receptor Tyrosine Kinase]] (Including [[VEGFR]] & [[PDGFR]]) & KIT Cytokine Receptor Inhibitor | ||
* Date of FDA Approval (Patent Expiration): 2005 (2020)<br /> | * Date of FDA Approval (Patent Expiration): 2005 (2020)<br /> | ||
* 2009 Sales: ~$904 Million<ref>http://quicktake.morningstar.com/Stocknet/san.aspx?id=358559</ref> | * 2009 Sales: ~$904 Million<ref>http://quicktake.morningstar.com/Stocknet/san.aspx?id=358559</ref> | ||
| Line 22: | Line 23: | ||
</tr> | </tr> | ||
</table> | </table> | ||
</StructureSection> | |||
===References=== | ===References=== | ||
<references/> | <references/> | ||
__NOEDITSECTION__ | __NOEDITSECTION__ | ||